TG THERAPEUTICS, INC. Cost of Revenue
TG THERAPEUTICS, INC. (TGTX) reported Cost of Revenue of $41.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- TG THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $41.19M, a 117.52% increase year-over-year.
- TG THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $33.51M, a 115.62% increase year-over-year.
- TG THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $38.14M, a 147.69% increase year-over-year.
- TG THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $28.09M, a 200.75% increase year-over-year.
- TG THERAPEUTICS, INC. cost of goods and services sold for fiscal 2025 was $100.71M, a 161.69% increase from fiscal 2024.
- TG THERAPEUTICS, INC. cost of goods and services sold for fiscal 2024 was $38.49M, a 172.35% increase from fiscal 2023.
- TG THERAPEUTICS, INC. cost of goods and services sold for fiscal 2023 was $14.13M, a 5232.45% increase from fiscal 2022.
- TG THERAPEUTICS, INC. cost of goods and services sold for fiscal 2022 was $265.00K, a 66.46% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.19M 10-Q · filed 2026-08-05 | $74.70M 10-Q · filed 2026-08-05 | $112.85M derived: sum of 3 quarters · filed 2026-08-05 | $140.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $33.51M 10-Q · filed 2026-05-06 | $71.65M derived: sum of 2 quarters · filed 2026-05-06 | $99.75M derived: sum of 3 quarters · filed 2026-05-06 | $118.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $38.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $66.23M derived: sum of 2 quarters · filed 2026-02-27 | $85.17M derived: sum of 3 quarters · filed 2026-08-05 | $100.71M 10-K · filed 2026-02-27 |
| 2025-09-30 | $28.09M 10-Q · filed 2025-11-05 | $47.03M derived: sum of 2 quarters · filed 2026-08-05 | $62.57M 10-Q · filed 2025-11-05 | $77.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $18.94M 10-Q · filed 2026-08-05 | $34.48M 10-Q · filed 2026-08-05 | $49.88M derived: sum of 3 quarters · filed 2026-08-05 | $59.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $15.54M 10-Q · filed 2026-05-06 | $30.94M derived: sum of 2 quarters · filed 2026-05-06 | $40.28M derived: sum of 3 quarters · filed 2026-05-06 | $48.59M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $15.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $24.74M derived: sum of 2 quarters · filed 2026-02-27 | $33.04M derived: sum of 3 quarters · filed 2026-02-27 | $38.49M 10-K · filed 2026-02-27 |
| 2024-09-30 | $9.34M 10-Q · filed 2025-11-05 | $17.64M derived: sum of 2 quarters · filed 2025-11-05 | $23.09M 10-Q · filed 2025-11-05 | $30.94M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $8.30M 10-Q · filed 2025-08-08 | $13.74M 10-Q · filed 2025-08-08 | $21.60M derived: sum of 3 quarters · filed 2026-02-27 | $25.11M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $5.44M 10-Q · filed 2025-05-09 | $13.29M derived: sum of 2 quarters · filed 2026-02-27 | $16.80M derived: sum of 3 quarters · filed 2026-02-27 | $18.71M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $7.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $11.36M derived: sum of 2 quarters · filed 2026-02-27 | $13.27M derived: sum of 3 quarters · filed 2026-02-27 | $14.13M 10-K · filed 2026-02-27 |
| 2023-09-30 | $3.51M 10-Q · filed 2024-11-07 | $5.42M derived: sum of 2 quarters · filed 2024-11-07 | $6.28M 10-Q · filed 2024-11-07 | $6.28M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.91M 10-Q · filed 2024-08-09 | $2.77M 10-Q · filed 2024-08-09 | $2.77M derived: sum of 3 quarters · filed 2025-03-03 | $2.77M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $857.00K 10-Q · filed 2024-05-06 | $860.00K derived: sum of 2 quarters · filed 2025-03-03 | $862.00K derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $5.00K derived: sum of 2 quarters · filed 2025-03-03 | $265.00K 10-K · filed 2025-03-03 | |
| 2022-09-30 | $2.00K 10-Q · filed 2023-11-06 | $262.00K 10-Q · filed 2023-11-06 | ||
| 2021-12-31 | $790.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |